Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-5: loncastuximab tesirine + rituximab versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
MOH_2021-06-23_010050Phase 3Recruiting
- Sponsor
- ADC Therapeutics
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of loncastuximab tesirine, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by ADC Therapeutics. Started May 2021; status: recruiting.
02
Drugs
loncastuximab tesirinerituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2021-06-23_010050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-23_010050.